Bio Essence Corporation
BIOE
$0.215
-$0.0201-8.55%
| Weiss Ratings | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.78 | |||
| Price History | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -20.37% | |||
| 30-Day Total Return | -15.32% | |||
| 60-Day Total Return | -14.00% | |||
| 90-Day Total Return | -91.40% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -17.31% | |||
| 2-Year Total Return | -60.91% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -98.01% | |||
| 52-Week Low % Change | 43.33% | |||
| Price | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.81 | |||
| 52-Week Low Price | $0.15 | |||
| 52-Week Low Price (Date) | May 24, 2024 | |||
| 52-Week High Price (Date) | Jul 02, 2024 | |||
| Valuation | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.17M | |||
| Enterprise Value | 11.28M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | 36.75% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 26.22 | |||
| Price/Book (Q) | -2.78 | |||
| Enterprise Value/Revenue (TTM) | 36.09 | |||
| Price | $0.22 | |||
| Enterprise Value/EBITDA (TTM) | -15.67 | |||
| Enterprise Value/EBIT | -16.04 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 38.01M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 706 9966 | |||
| Address | 12 Chrysler Unit B Irvine, CA 92618 | |||
| Website | www.bioessencecorp.com | |||
| Country | United States | |||
| Year Founded | 2000 | |||
| Profitability | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -225.01% | |||
| Profit Margin | -471.84% | |||
| Management Effectiveness | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.79% | |||
| Return on Equity | -- | |||
| Income Statement | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 312.60K | |||
| Total Revenue (TTM) | 312.60K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 257.70K | |||
| EBITDA (TTM) | -720.20K | |||
| EBIT (TTM) | -703.40K | |||
| Net Income (TTM) | -1.48M | |||
| Net Income Avl. to Common (TTM) | -1.48M | |||
| Total Revenue Growth (Q YOY) | -13.49% | |||
| Earnings Growth (Q YOY) | -281.04% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | -280.72% | |||
| Balance Sheet | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 29.80K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 715.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.94M | |||
| Current Ratio (Q) | 0.233 | |||
| Book Value Per Share (Q) | -$0.08 | |||
| Total Assets (Q) | 716.00K | |||
| Total Current Liabilities (Q) | 3.07M | |||
| Total Debt (Q) | 3.14M | |||
| Total Liabilities (Q) | 3.66M | |||
| Total Common Equity (Q) | -2.94M | |||
| Cash Flow | BIOE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -87.90K | |||
| Cash from Financing (TTM) | 121.00K | |||
| Net Change in Cash (TTM) | 29.90K | |||
| Levered Free Cash Flow (TTM) | -536.40K | |||
| Cash from Operations (TTM) | -3.30K | |||
